AngioDynamics (ANGO) Tops Q4 EPS by 3c; Affirms FY18 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 6:00 AM EDTCompany posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance
Q4 net sales of $86.9 million, down 7% year-over-yearQ4 GAAP loss per share of $0.30; adjusted EPS of $0.19Full Year net sales of $349.6 million, down 1% year-over-yearFull Year GAAP earnings per share of $0.19; Adjusted EPS of $0.73, up 22% compared to FY2016Full Year operating cash generation of $55.7 million; free cash flow generation of $52.7 millionALBANY, N.Y., July 18, 2017 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ: ANGO), a leading provider of innovative, minimally invasive... More
